This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Revuforj (revumenib)
General Description:
Revuforj (revumenib) is an oral prescription medication indicated for the treatment of relapsed or refractory acute leukemia with a KMT2A (lysine methyltransferase 2A) gene translocation in adults and pediatric patients aged 1 year and older. It works by selectively inhibiting the menin-KMT2A interaction, helping to slow disease progression and improve patient outcomes.
Revuforj is administered orally as tablets, with dosage and treatment schedules determined by a qualified healthcare professional based on patient condition and response.
Getting Revuforj (revumenib) in India
Revuforj is currently approved only in the USA. While it may not yet be commercially available in India, patients can access it legally through a Named Patient Program (NPP) under the guidance of a licensed physician.
MitoGENE assists Indian patients in obtaining Revuforj safely, managing all regulatory approvals, import permits, and logistics to ensure a secure and compliant process.
Disease Indication:
• Leukemia / Relapsed or Refractory Acute Leukemia with KMT2A Translocation
Manufacturer:
Servier Pharmaceuticals
Usage:
Oral Tablets
Medicine Approved By:
• Food and Drug Administration (FDA)
Available Dosage Form & Package:
• 30 tablets x 25 mg
• 30 tablets x 110 mg
• 30 tablets x 160 mg
Shipping:
Room Temperature Shipping
Revuforj is shipped under controlled room temperature conditions (15–25°C) to maintain stability and effectiveness. Standard shipping procedures ensure the medication remains safe and uncompromised during transit.
How to Access Revuforj (revumenib) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Revuforj (revumenib) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
